Literature DB >> 31617124

Therapeutic potential of aryl hydrocarbon receptor in autoimmunity.

Xiao-Song Wang1,2, Fan Cao3, Yi Zhang4, Hai-Feng Pan5,6.   

Abstract

Aryl hydrocarbon receptor (AhR), a type of transcriptional factor, is widely expressed in immune cells. The activation of AhR signaling pathway depends on its ligands, which exist in environment and can also be produced by metabolism. Normal expressions of AhR and AhR-mediated signaling may be essential for immune responses, and effects of AhR signaling on the development and function of innate and adaptive immune cells have also been revealed in previous studies. Recent studies also indicate that aberrant AhR signaling may be related to autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), autoimmune uveitis (AU), autoimmune diabetes, Behcet's disease (BD) and myasthenia gravis (MG). Moreover, administration of AhR ligands or drugs has been proven effective for improving pathological outcomes in some autoimmune diseases or models. In this review, we summarize the effects of AhR on several innate and adaptive immune cells associated with autoimmunity, and the mechanism on how AhR participates in autoimmune diseases. In addition, we also discuss therapeutic potential and application prospect of AhR in autoimmune diseases, so as to provide valuable information for exploring novel and effective approaches to autoimmune disease treatments.

Entities:  

Keywords:  AhR; Aryl hydrocarbon receptor; Autoimmune diseases; Autoimmunity; Therapeutics

Year:  2019        PMID: 31617124     DOI: 10.1007/s10787-019-00651-z

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  5 in total

1.  Drug delivery of 6-bromoindirubin-3'-glycerol-oxime ether employing poly(D,L-lactide-co-glycolide)-based nanoencapsulation techniques with sustainable solvents.

Authors:  Anna Czapka; Christian Grune; Patrick Schädel; Vivien Bachmann; Karl Scheuer; Michael Dirauf; Christine Weber; Alexios-Leandros Skaltsounis; Klaus D Jandt; Ulrich S Schubert; Dagmar Fischer; Oliver Werz
Journal:  J Nanobiotechnology       Date:  2022-01-04       Impact factor: 10.435

2.  The Contribution of Genetic Variation and Aberrant Methylation of Aryl Hydrocarbon Receptor Signaling Pathway Genes to Rheumatoid Arthritis.

Authors:  Tian-Ping Zhang; Rui Li; Hong-Miao Li; Nan Xiang; Zhen Tan; Guo-Sheng Wang; Xiao-Mei Li
Journal:  Front Immunol       Date:  2022-03-02       Impact factor: 7.561

3.  E3 ubiquitin ligases STUB1/CHIP contributes to the Th17/Treg imbalance via the ubiquitination of aryl hydrocarbon receptor in rheumatoid arthritis.

Authors:  Wen Wang; Ting Xiang; Yachen Yang; Zitao Wang; Jianmin Xie
Journal:  Clin Exp Immunol       Date:  2022-09-29       Impact factor: 5.732

Review 4.  Herbal Plants: The Role of AhR in Mediating Immunomodulation.

Authors:  Izzah Bungsu; Nurolaini Kifli; Siti Rohaiza Ahmad; Hazim Ghani; Anne Catherine Cunningham
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

Review 5.  What If Not All Metabolites from the Uremic Toxin Generating Pathways Are Toxic? A Hypothesis.

Authors:  Raymond Vanholder; Sanjay K Nigam; Stéphane Burtey; Griet Glorieux
Journal:  Toxins (Basel)       Date:  2022-03-17       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.